Brief: Tonix Pharmaceuticals receives MCDC grant for devloping its single-dose Mpox and Smallpox vaccine
10/03/2025 14:34
March 10 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES GRANT BY MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) FOR DEVELOPMENT OF TNX-801, THE COMPANY’S SINGLE-DOSE MPOX AND SMALLPOX VACCINE CANDIDATE TONIX PHARMACEUTICALS: TOLERABILITY OF TNX‐801 VACCINATION IN IMMUNE-COMPROMISED ANIMAL MODELS SUPPORTS CLINICAL DEVELOPMENT Source text: nGNX5xStzg Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview